Search results for "Clear Cell Renal Carcinoma"

showing 3 items of 3 documents

Metastatic Renal Cell Carcinoma to Submandibular Gland: A Rare Occurrence

2015

Approximately 20-30% of patients affected by renal cell carcinoma (RCC) present with metastatic disease, and 20% to 40% undergoing nephrectomy for clinically localized disease will develop metastases. A 53 years old female patient developed a left submandibular swelling. Four years before she experienced a left radical nephrectomy for a clear cell tumor and two years later right kidney was removed for a cancer having the same histologic subtype. In that circumstance duodenal pancreasectomy was required for infiltration of pancreatic gland. A sialoadenectomy has been performed and pathology demonstrated an intraglandular neoplasm with characteristics of a clear renal cell carcinoma. Although…

Pathologymedicine.medical_specialtymedicine.medical_treatmentSettore MED/19 - Chirurgia PlasticaMetastasiurologic and male genital diseasesSettore MED/24 - UrologiaMetastasisstomatognathic systemRenal cell carcinomamedicineClear cell renal carcinomaSalivary gland metastasisSubmandibular glandKidneySalivary glandbusiness.industryGeneral Medicinemedicine.diseaseSubmandibular glandNephrectomymedicine.anatomical_structureLocalized diseaseClear cell renal carcinoma; Metastasis; Submandibular gland; Salivary gland metastasisbusinessClear cellAnaplastology
researchProduct

Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.

2021

Abstract Introduction Renal cell carcinoma (RCC) accounts for 2–3% of all tumors being the most frequent solid lesion in the kidney. Objective To determine what genetic alterations and immunohistochemical (IHC) of clear cell renal carcinoma (ccRCC) are associated with prognosis and tumor aggressiveness. Patients and Methods Experimental analytical study with 57 patients who underwent radical and partial nephrectomy between 2005 and 2011, all with diagnosis of ccRCC and minimum post-operative follow-up of 36 months. The pathological study included IHC determination of biomarkers associated (CAIX, CAM 5.2, CD10, c-erbB-2, EGFR, HIF-1a, Ki67, MDM2, PAX-2 y 8, p53, survivin and VEGFR 1 and 2). …

p530301 basic medicineMaleCancer Researchmedicine.medical_treatmentGastroenterologyNephrectomy0302 clinical medicineFHITRenal cell carcinomaCDKN2ANeoplasm MetastasisClear cell renal carcinomaRC254-282KidneyBRCA1 y 2Neoplasms. Tumors. Oncology. Including cancer and carcinogensCDKN2A: cyclin-dependent kinase Inhibitor 2AMiddle AgedPrognosisImmunohistochemistryNephrectomyKidney NeoplasmsMLPATumor BurdenSurvival Ratemedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.medical_specialty03 medical and health sciencesInternal medicinemedicineHumansMultiplex ligation-dependent probe amplificationCarbonic Anhydrase IXSurvival rateCarcinoma Renal CellAgedNeoplasm Stagingbusiness.industryCAIXmedicine.disease030104 developmental biologyNeoplasm GradingNeoplasm Recurrence LocalbusinessTranscriptomeFollow-Up StudiesCancer treatment and research communications
researchProduct

738P Soluble PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTN2A1 as predictive biomarkers of nivolumab response in patients with metastatic clear cell renal c…

2020

Oncologymedicine.medical_specialtybiologybusiness.industryHematologyOncologyInternal medicinePD-L1Clear Cell Renal Carcinomamedicinebiology.proteinIn patientNivolumabbusinessPredictive biomarkerAnnals of Oncology
researchProduct